Recent Trends in Nanocarrier-Based Drug Delivery System for Prostate Cancer
Prostate cancer remains a significant global health concern, requiring innovative approaches for improved therapeutic outcomes. In recent years, nanoparticle-based drug delivery systems have emerged as promising strategies to address the limitations of conventional cancer chemotherapy. The key trends include utilizing nanoparticles for enhancing drug delivery to prostate cancer cells. Nanoparticles have some advantages such as improved drug solubility, prolonged circulation time, and targeted delivery of drugs. Encapsulation of chemotherapeutic agents within nanoparticles allows for controlled release kinetics, reducing systemic toxicity while maintaining therapeutic efficacy. Additionally, site-specific accumulation within the prostate tumor microenvironment is made possible by the functionalization of nanocarrier with targeted ligands, improving therapeutic effectiveness. This article highlights the basics of prostate cancer, statistics of prostate cancer, mechanism of multidrug resistance, targeting approach, and different types of nanocarrier used for the treatment of prostate cancer. It also includes the applications of nanocarriers for the treatment of prostate cancer and clinical trial studies to validate the safety and efficacy of the innovative drug delivery systems. The article focused on developing nanocarrier-based drug delivery systems, with the goal of translating these advancements into clinical applications in the future. Graphical Abstract.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
AAPS PharmSciTech - 25(2024), 3 vom: 06. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kumar, Amit [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
Clinical trials |
| Anmerkungen: |
© The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1208/s12249-024-02765-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR055044735 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR055044735 | ||
| 003 | DE-627 | ||
| 005 | 20240327064925.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240307s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1208/s12249-024-02765-2 |2 doi | |
| 035 | |a (DE-627)SPR055044735 | ||
| 035 | |a (SPR)s12249-024-02765-2-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 084 | |a 44.40 |2 bkl | ||
| 100 | 1 | |a Kumar, Amit |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Recent Trends in Nanocarrier-Based Drug Delivery System for Prostate Cancer |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Prostate cancer remains a significant global health concern, requiring innovative approaches for improved therapeutic outcomes. In recent years, nanoparticle-based drug delivery systems have emerged as promising strategies to address the limitations of conventional cancer chemotherapy. The key trends include utilizing nanoparticles for enhancing drug delivery to prostate cancer cells. Nanoparticles have some advantages such as improved drug solubility, prolonged circulation time, and targeted delivery of drugs. Encapsulation of chemotherapeutic agents within nanoparticles allows for controlled release kinetics, reducing systemic toxicity while maintaining therapeutic efficacy. Additionally, site-specific accumulation within the prostate tumor microenvironment is made possible by the functionalization of nanocarrier with targeted ligands, improving therapeutic effectiveness. This article highlights the basics of prostate cancer, statistics of prostate cancer, mechanism of multidrug resistance, targeting approach, and different types of nanocarrier used for the treatment of prostate cancer. It also includes the applications of nanocarriers for the treatment of prostate cancer and clinical trial studies to validate the safety and efficacy of the innovative drug delivery systems. The article focused on developing nanocarrier-based drug delivery systems, with the goal of translating these advancements into clinical applications in the future. Graphical Abstract | ||
| 650 | 4 | |a clinical trials |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a multidrug resistance |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a nanocarriers |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a prostate cancer |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a targeting approach |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Lunawat, Akshay Kumar |4 aut | |
| 700 | 1 | |a Kumar, Ashutosh |4 aut | |
| 700 | 1 | |a Sharma, Tarun |4 aut | |
| 700 | 1 | |a Islam, Md Moidul |4 aut | |
| 700 | 1 | |a Kahlon, Milan Singh |4 aut | |
| 700 | 1 | |a Mukherjee, Debanjan |4 aut | |
| 700 | 1 | |a Narang, Raj Kumar |4 aut | |
| 700 | 1 | |a Raikwar, Sarjana |0 (orcid)0000-0002-1476-9684 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t AAPS PharmSciTech |d Springer International Publishing, 2000 |g 25(2024), 3 vom: 06. März |w (DE-627)SPR02478785X |w (DE-600)2052070-0 |x 1530-9932 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2024 |g number:3 |g day:06 |g month:03 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1208/s12249-024-02765-2 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 936 | b | k | |a 44.40 |q VZ |
| 951 | |a AR | ||
| 952 | |d 25 |j 2024 |e 3 |b 06 |c 03 | ||